Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model
Table 2
Resveratrol improved left ventricular function in ISO-treated rats and reduced left ventricular hypertrophy.
Baseline
C
RES
ISO
ISO + RES
EF (%)
75.62 ± 0.87
71.70 ± 1.61
72.47 ± 1.69
56.96 ± 1.43#
67.49 ± 1.14
Septum (mm)
1.63 ± 0.05
1.65 ± 0.10
1.61 ± 0.03
1.82 ± 0.03#
1.70 ± 0.02
PW (mm)
1.57 ± 0.03
1.59 ± 0.07
1.59 ± 0.03
1.81 ± 0.06#
1.60 ± 0.02
LVIDd (mm)
8.19 ± 0.11
8.44 ± 0.22
8.43 ± 0.17
7.88 ± 0.12
8.41 ± 0.23
LVIDs (mm)
4.42 ± 0.08
4.85 ± 0.09
4.69 ± 0.19
5.70 ± 0.2#
4.90 ± 0.12
LVEDV (μl)
364.23 ± 10.38
393.36 ± 19.32
386.40 ± 16.82
365.54 ± 6.64
401.59 ± 18.63
LVESV (μl)
88.83 ± 4.40
109.9 ± 4.53
106.14 ± 7.26
157.71 ± 7.29#
130.27 ± 6.69
LV mass (mg)
994.1 ± 21.8
1035.31 ± 59.79
1038.38 ± 44.44
1239.14 ± 76.5#
1041.85 ± 35.50
C: control group; RES: resveratrol group; ISO: isoproterenol-treated group; ISO + RES: ISO + resveratrol group. EF: ejection fraction; LVESV: left ventricular end-systolic volume; LVEDV: left ventricular end-diastolic volume; LVIDd: diastolic left ventricular inner diameter; LVIDs: systolic left-ventricular inner diameter. The results are expressed as mean ± SEM. # versus control. versus ISO.
